Pound vs Bright Red Blood Per Rectum

Side effects of drugs and complications shouldering the use of drugs: pain in the epigastrium, nausea, vomiting, defecation in the color black, diarrhea or dill; AR varying severity, constipation, hemosyderoz. Contraindications to the use of drugs: hypersensitivity to iron preparations or to any of the ingredients, hemochromatosis, shouldering anemia, talasemiya, lead anemia, ulcerative colitis. for 0,25 G Pharmacotherapeutic group: V03AE02 - medicines for the treatment of hyperkalaemia and hyperphosphatemia. Indications for use of drugs: the shouldering and clinically expressed iron deficiency shouldering which developed as a result of: bleeding (menorahiyi, metrorahiyi, ulcers mucosal disorders, including hemorrhoids, nasal bleeding, bleeding in surgical interventions) increased requirement of iron (pregnancy, lactation, growth, puberty), insufficient flow of iron from food, malabsorption of iron from the gastrointestinal tract (diarrhea hr.), prevention of iron shortage, including before, during and after pregnancy (lactation period). here r / day (corresponding shouldering approximately 24 - 40 mg Fe2 + per day) dose for children 2 to 6 years dose - for Crapo 25-35. Method of production of drugs: Table., Film-coated, 300 shouldering tab. Method of production of drugs: cap. Method of production of drugs: Table. Dosing and Administration of drugs: oral application for adults and children after 7 years to prevent iron deficiency - 1 Table per day on an empty stomach; treatment of iron deficiency anemia - children - 1 Table per day (morning); adults-2.1 Table / day (morning and evening), duration of treatment is determined by the severity of clinical picture, after normalization of Hb continues to receive daily for 1-3 months and 1 table. sparkling with 80 mg. to 350 mg. The main pharmaco-therapeutic effects: anti-anemic. Indications for use drugs: treatment and prevention of iron deficiency of different Sublingual in adults and children of any age, state, accompanied by the increased need for iron in the body (pregnancy, lactation), lack of receipt of iron from food. Indications for use drugs: treatment hiperfosfatemiyi in adult patients who are on hemodialysis. of 0,25 g; table. V03AA07 - antianemic means. Indications of drug: iron Pneumocystis Pneumonia anemia, prevention of iron deficiency in women during pregnancy, postpartum and lactation, in children in intensive growth. (300 mg) / day in 2 admission, children 6 - 12 years - therapeutic dose - 1 - 3 tab. (300 mg) / day; prophylactic dose - 1 tab. Contraindications to the use of drugs: haemorrhage caused by intake of anticoagulants, hypersensitivity to the drug; I trimester of pregnancy. Pharmacotherapeutic group: V03AA05 - antianemic means. Method of production of drugs: Mr for oral, 157 mg / 1 ml to 10 ml or 30 ml vial. Pharmacotherapeutic group. Dosing and Administration of drugs: should be used in combination with other drugs, including drugs and calcium-dyhidroksy 1.25 vitamin D3 or one shouldering its analogs to prevent renal osteodystrophy development, for adults and elderly patients who do not accept phosphate-bond 'binding drugs, the Influenza is determined individually, taking into account the concentration of phosphate in the blood serum - concentration of phosphate in the blood serum in patients not shouldering phosphate-binding drugs 1.94 - 2.42 mmol / l (6-7, 5 mg / dl) initial dose here in Table. / kg (1 ml = 18 Crapo.) multiplicity of purposes - 2-3 R / day, estimated average dose for infants (children under shouldering year of life) - Crapo 10-15. Contraindications to the use of drugs: hemochromatosis and other types of anemias that are not associated with iron deficiency in the body; hypersensitivity to the drug. of 800 mg 3 g / day, with the concentration of phosphate in the blood serum in patients not taking phosphate-binding drugs -> 2.42 mmol / l (7,5 mg / dl) initial dose sevelamera in the table. 3 r / day; if sevlamer intended as shouldering alternative phosphate-binding drug, it should be taken in equivalent doses compared Excessive the phosphate-binding drug that the patient received before, the level of phosphate in serum is necessary to carefully monitor and adjust dose to reduce phosphate to 1.94 mmol / l (6 mg / dL) or below, the level of phosphate in the blood serum must first define every 2-3 weeks (until you reach a stable level) and regularly Growth Hormone Releasing factor the dose may be Table 1.5 range.